Oncotelic Therapeutics, Inc. Equity Securities, FV-NI, Unrealized Gain
Oncotelic Therapeutics, Inc. (OTLC) reported Equity Securities, FV-NI, Unrealized Gain of $300.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2026-08-13
- Oncotelic Therapeutics, Inc. equity securities, fv-ni, unrealized gain for the quarter ending 2026-06-30 was -$365.15M.
- Oncotelic Therapeutics, Inc. equity securities, fv-ni, unrealized gain for the quarter ending 2026-03-31 was $365.45M.
- Oncotelic Therapeutics, Inc. equity securities, fv-ni, unrealized gain for fiscal 2023 was $12.71K.
| Period end | Equity Securities, FV-NI, Unrealized Gain 3 month | Equity Securities, FV-NI, Unrealized Gain 6 month | Equity Securities, FV-NI, Unrealized Gain 12 month |
|---|---|---|---|
| 2026-06-30 | -$365.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $300.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $365.45M 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $365.35M 10-Q · filed 2026-08-13 | ||
| 2023-12-31 | $12.71K 10-K · filed 2025-04-15 |